Variable
|
Axitinib
|
Sunitinib
|
Sorafenib
|
P
1
|
P
2
|
P
3
|
---|
Maximal diameter (cm)a
|
Before therapy
|
7.2 (6.2–8.5)
|
6.4 (5.7–10.3)
|
6.8 (5.8–11.0)
|
0.497
|
0.664
|
0.868
|
After therapy
|
5.2 (4.4–7.4)
|
5.6 (5.1–9.8)
|
6.4 (4.8–6.4)
|
0.266
|
0.284
|
0.657
|
Reduction
|
1.5 (1.2–2.2)
|
0.8 (0.5–1.1)
|
0.5 (0.4–0.8)
|
0.001
|
< 0.001
|
0.024
|
Reduction rate (%)a
|
22.4 (13.8–30)
|
12.2 (7.1–14.1)
|
6.9 (3.7–12.0)
|
0.001
|
0.001
|
0.023
|
> 10% reduction [cases (%)]
|
13 (86.7)
|
16 (66.7)
|
8 (26.7)
|
0.310*
|
0.001*
|
0.003*
|
- P1, axitinib vs. sunitinib; P2, axitinib vs. sorafenib; P3, sunitinib vs. sorafenib
- P, Wilcoxon signed-rank test; P*, Pearson’s Chi square test
- aThe data are presented as median (interquartile range)